Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Soft Tissue Sarcoma | Research

Amputation in patients with extremity soft tissue sarcoma: the experience of an East Asian referral center

Authors: Yongsung Kim, Han-Soo Kim, Ilkyu Han

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

This study aimed to investigate the characteristics and clinical outcomes in a series of patients with extremity soft tissue sarcoma (STS) who underwent amputation at a large East Asian referral center.

Patients and methods

Of the 652 patients who underwent surgery for extremity STS, data of 37 consecutive patients who underwent amputation were reviewed retrospectively. The median follow-up period was 96.0 months (range, 15–216). The patients were classified in to three cohorts. The primary localized (PL) group included patients who underwent amputation as a primary surgical procedure with curative intent. The recurrent localized (RL) group included patients who underwent amputation as a revision procedure after failure of previous limb sparing surgeries. The metastatic group included patients who underwent amputation as a palliative procedure.

Results

There were 22 cases of amputation in 596 STS patients and the amputation rate was 3.6% (22/596). Further, 1.8% (9/490) of patients with primary localized STS underwent amputation. Patients with localized STS who underwent amputation had a 5-year disease-specific survival (DSS) rate of 89.9% (95% Confidence Interval (CI), 87.1–92.7%), a local-recurrence-free survival (LRFS) of 84.1% (95% CI, 80.5–87.6%), and a metastasis-free survival (MFS) of 84.6%. (95% CI, 81.1–88.0%) Compared with previous studies, our results showed higher DSS and MFS rates with similar LRFS.

Conclusions

The amputation rate of extremity STS in our institute in East Asia was similar but slightly lower than that reported in Western studies. The oncologic outcome of amputation reported in this study was higher than that indicated in Western studies and oncologic outcome of amputation was not statistically different from those of limb salvage surgery. However, considering the small cohort in single institute study, there is a possibility of selection bias and future multi-center study is necessary. From our results, amputation is still a feasible option for appropriately selected patients unsuitable for limb-conserving surgery.
Literature
1.
Eilber FR, Mirra JJ, Grant TT, Weisenburger T, Morton DL. Is amputation necessary for sarcomas? A seven-year experience with limb salvage. Ann Surg. 1980;192(4):431–8.CrossRefPubMedPubMedCentral
2.
Suit HD, Russell WO, Martin RG. Management of patients with sarcoma of soft tissue in an extremity. Cancer. 1973;31(5):1247–55.CrossRefPubMed
3.
4.
Pisters PW, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, Feig BW, Hunt KK, Lin PP, Zagars G, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246(4):675–81. discussion 681– 672.CrossRefPubMed
5.
Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.CrossRefPubMedPubMedCentral
6.
Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215(3):269–75.CrossRefPubMedPubMedCentral
7.
Bickels J, Wittig JC, Kollender Y, Kellar-Graney K, Malawer MM, Meller I. Sciatic nerve resection: is that truly an indication for amputation? Clin Orthop Relat Res. 2002;399:201–4.CrossRef
8.
9.
Ferrone ML, Raut CP. Modern surgical therapy: limb salvage and the role of amputation for extremity soft-tissue sarcomas. Surg Oncol Clin N Am. 2012;21(2):201–13.CrossRefPubMed
10.
Henshaw RM, Priebat DA, Perry DJ, Shmookler BM, Malawer MM. Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol. 2001;8(6):484–95.CrossRefPubMed
11.
12.
Trovik CS, Scanadinavian Sarcoma Group P. Local recurrence of soft tissue sarcoma. A scandinavian Sarcoma Group Project. Acta Orthop Scand Suppl. 2001;72(300):1–31.PubMed
13.
Smith HG, Thomas JM, Smith MJF, Hayes AJ, Strauss DC. Major amputations for extremity Soft-Tissue Sarcoma. Ann Surg Oncol. 2018;25(2):387–93.CrossRefPubMed
14.
Morton DL, Eilber FR, Townsend CM Jr., Grant TT, Mirra J, Weisenburger TH. Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity. Ann Surg. 1976;184(3):268–78.CrossRefPubMedPubMedCentral
15.
Ghert MA, Abudu A, Driver N, Davis AM, Griffin AM, Pearce D, White L, O’Sullivan B, Catton CN, Bell RS, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol. 2005;12(1):10–7.CrossRefPubMed
16.
Mann GN. Less is (usually) more: when is amputation appropriate for treatment of extremity soft tissue sarcoma? Ann Surg Oncol. 2005;12(1):1–2.CrossRefPubMed
17.
Ngan R, Wang E, Porter D, Desai J, Prayogo N, Devi B, Quek R. Soft-tissue sarcomas in the Asia-Pacific region: a systematic review. Asian Pac J Cancer Prev. 2013;14(11):6821–32.CrossRefPubMed
18.
Hagi T, Nakamura T, Nagano A, Koike H, Yamada K, Aiba H, Fujihara N, Wasa J, Asanuma K, Kozawa E, et al. Clinical outcome in patients who underwent amputation due to extremity soft tissue sarcoma: Tokai Musculoskeletal Oncology Consortium study. Jpn J Clin Oncol. 2022;52(2):157–62.CrossRefPubMed
19.
Lazarides AL, Visgauss JD, Nussbaum DP, Green CL, Blazer DG 3rd, Brigman BE, Eward WC. Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities. BMC Cancer. 2018;18(1):488.CrossRefPubMedPubMedCentral
20.
Martinez SR, Robbins AS, Meyers FJ, Bold RJ, Khatri VP, Goodnight JE Jr. Racial and ethnic differences in treatment and survival among adults with primary extremity soft-tissue sarcoma. Cancer. 2008;112(5):1162–8.CrossRefPubMed
21.
Rosenberg SA, Kent H, Costa J, Webber BL, Young R, Chabner B, Baker AR, Brennan MF, Chretien PB, Cohen MH, et al. Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery. 1978;84(1):62–9.PubMed
22.
Erstad DJ, Ready J, Abraham J, Ferrone ML, Bertagnolli MM, Baldini EH, Raut CP. Amputation for Extremity Sarcoma: contemporary indications and outcomes. Ann Surg Oncol. 2018;25(2):394–403.CrossRefPubMed
23.
Stevenson MG, Musters AH, Geertzen JHB, van Leeuwen BL, Hoekstra HJ, Been LB. Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: local control and survival. J Surg Oncol. 2018;117(3):434–42.CrossRefPubMed
24.
van Houdt WJ, Griffin AM, Wunder JS, Ferguson PC. Oncologic outcome and quality of Life after Hindquarter Amputation for Sarcoma: is it worth it? Ann Surg Oncol. 2018;25(2):378–86.CrossRefPubMed
25.
McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY. A patient’s race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum. 2006;49(3):319–29.CrossRefPubMed
26.
Song YJ. The South Korean health care system. Jmaj. 2009;52(3):206–9.
27.
Keus RB, Rutgers EJ, Ho GH, Gortzak E, Albus-Lutter CE, Hart AA. Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results. Eur J Cancer. 1994;30A(10):1459–63.CrossRefPubMed
28.
Williard WC, Collin C, Casper ES, Hajdu SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet. 1992;175(5):389–96.PubMed
29.
Alamanda VK, Crosby SN, Archer KR, Song Y, Schwartz HS, Holt GE. Amputation for extremity soft tissue sarcoma does not increase overall survival: a retrospective cohort study. Eur J Surg Oncol. 2012;38(12):1178–83.CrossRefPubMed
30.
Stojadinovic A, Jaques DP, Leung DH, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol. 2001;8(6):509–18.CrossRefPubMed
31.
Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol. 1987;5(4):601–12.CrossRefPubMed
32.
33.
Metadata
Title
Amputation in patients with extremity soft tissue sarcoma: the experience of an East Asian referral center
Authors
Yongsung Kim
Han-Soo Kim
Ilkyu Han
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11813-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma

Research

Analysis of correlative risk factors for radiation-induced hypothyroidism in head and neck tumors

Research

LABS score– a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study

Research

Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data

Research

Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

Research

Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits